LONDON – Sequana Medical NV closed a €8.5 million (US$9.9 million) round, providing the means to scale up commercial operations in Europe and prepare the way for two U.S. studies of its Alfapump device, in the treatment of liver ascites and the management of fluid volume overload in heart failure.